![Anaemia icon](/dam/jcr:8a62052e-4818-4e58-83df-f96c6e08b6ea/Group%206338.png)
CAD is a rare, chronic, autoimmune haemolytic anaemia that shouldn’t be confused with cold agglutinin syndrome (CAS) secondary to infection or cancer1,4
![C1 activation icon](/dam/jcr:6386be32-0e62-4c77-8ad4-78fd5bf4f7d9/Group%206341.png)
In CAD, activated C1 triggers the classical complement pathway and drives chronic haemolysis4
![Risk icon](/dam/jcr:1a8369a6-7787-43f6-aa73-2a35753f3830/Group%206342.png)
Patients can face risks for severe anaemia and possible life-threatening TEs despite current management3,5
![Fatigue icon](/dam/jcr:12be0b61-3498-4b0c-9e0f-e64ba495ba2a/Group%201411.png)
Profound fatigue and life-limiting burden persist despite current management6-10
There are specific criteria to diagnose CAD
See the goals for future CAD treatment
Sanofi is committed to ongoing CAD research.
CAD=Cold Agglutinin Disease; CAS=cold agglutinin syndrome; TE=thromboembolic event.
References: 1. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12(5):361-370. doi:10.1080/10245330701445392 2. Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848. doi:10.1182/bloodadvances.2017004390 3. Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4(4):628-635. doi:10.1002/rth2.12333 4. Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55(3):141-149. doi:10.1053/j.seminhematol.2018.04.002 5. Kamesaki T, Nishimura J-i, Wada H, et al. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020:112(3):307-315. doi:10.1007/s12185-020-02899-6 6. Su J, Kosa K, DiBenedetti D. Patient-reported disease burden: in-depth interviews of patients with CAD. Blood. 2020;136(suppl 1):29-30. doi:10.1182/blood-2020-136788
7. Patel P, Jiang X, Nicholson G et al. Medically attended anxiety or depression is increased among newly diagnosed patients with cold agglutinin disease (CAD). Blood. 2020;136(suppl 1):28. doi.org/10.1182/blood-2020-139791 8. Vágó EK, Nicholson G, Horváth-Puhó E, Hooda N, Fryzek JP, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin. 2021;37(10):1829-1835. doi: 10.1080/03007995.2021.1960494 9. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121. doi:10.1182/blood-2013-02-474437 10. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107-115. doi:10.1016/j.blre.2012.01.002
MAT-GLB-2201058-v1.0-05/2022